|
|
市场分析报告
|
Antibody Drug Conjugates Market Size, Trends, Analysis, and Outlook By Product (Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, Others), By Disease (Breast Cancer, Blood Cancer, Others), By Linker (Non-Cleavable, Cleavable), By Target, HER2, CD22, CD30, Others), By Payload (MMAE/auristatin, calicheamicin, Maytansinoids, Others), by Country, Segment, and Companies, 2024-2032
... , CD22, CD30, Others), By Payload (MMAE/auristatin, calicheamicin, Maytansinoids, Others) The antibody ... CD22 CD30 Others By Payload MMAE/auristatin calicheamicin Maytansinoids Others Geographical Segmentation ...
Antibody Drug Conjugate Market (7th Edition), 2023-2035: Distribution by Target Disease Indication (Breast Cancer, B-cell Lymphoma, Lung Cancer, Multiple Myeloma, Acute Lymphoblastic Leukemia, Gastric Cancer, Renal Cancer, Cervical Cancer and Other Target Disease Indications), Therapeutic Area (Hematological Cancer and Solid Tumor), Linker (Valine-Citrulline, Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate, Tetrapeptide-based Linker, Maleimide, Maleimidocaproyl, Valine-Alanine, Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (AcBut) and Other Linkers), Payload (Monomethyl Auristatin E, DM1, Duocarmycin, SN-38 / Irinotecan, Monomethyl Auristatin F, SG3199, Ozogamicin, DM4 and Other Payloads), Target Antigens (HER-2 (ERBB2), CD79b, Trop-2, BCMA (TNFRSF17 / BCM), CD19, CD22, Tissue Factor, CD30, CEACAM5, Nectin 4 and Others) And Key Geographical Regions (North America (US, Canada), Europe (Germany, UK, France, Italy, Spain), and Asia-Pacific (China, Australia, Japan)): Industry Trends and Global Forecasts
The global antibody drug conjugate market is expected to reach USD 7.72 billion by 2023 and is anticipated to grow at a CAGR of 9.63% during the forecast period 2023-2035 Antibody drug conjugates (ADCs) are a class of engineered therapeutics that combine ...
ADC Payload / Warheads Market: Distribution by Type of Product (Commercialized ADCs and Clinical ADCs), Type of Payload (Microtubule Inhibitors, DNA Damaging Agents, Topoisomerase Inhibitors and Others), Payload / Warhead (Auristatins, Calicheamicin, Camptothecin, Duocarmycin, Maytansinoids, Pyrrolobenzodiazepines and Others) and Geography (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2035
... Inhibitors and Others), Payload / Warhead (Auristatins, Calicheamicin, Camptothecin, Duocarmycin, Maytansinoids, ... Topoisomerase Inhibitors Others Payload / Warhead Auristatins Calicheamicin Camptothecin Duocarmycin Maytansinoids Pyrrolobenzodiazepines ...
Celldex Therapeutics, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
... to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The CR011 antibody specifically ... -014, is linked to a potent chemotherapeutic, monomethyl auristatin E (MMAE), using Seattle Genetics' proprietary ...
Seattle Genetics Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis
... class of cell-killing drugs called auristatins. The CD30 antigen is a target for ... -CD70 monoclonal antibody linked to a potent auristatin compound using proprietary ADC technology ...
ADC Contract Manufacturing Market (5th Edition) by Phase of Development (Phase I, Phase II and Phase III), Scale of Operation (Clinical and Commercial), Type of Component Manufacturing (Antibody Manufacturing, HPAPI / Cytotoxic Payload, Linker and Conjugation Manufacturing, and Fill / Finish), Target Indications (Solid Tumors, Hematological Malignancies and Others), Type of Payload (Maytansinoid, Auristatin, Camptothecin, PBD and Others), Type of Linker (SMCC, VC, Malemide, Peptide Linker and Others), Type of Antibody Origin (Humanized, Chimeric, Murine, Human and Others), Antibody Isotype (IgG1and Others) and Geography (North America, Europe, Asia-Pacific and Rest of the World), 2022-2035
The ADC contract manufacturing market is expected to reach USD 2.8 billion by 2022 anticipated to grow at a CAGR of 11.8% during the forecast period 2022-2035. Over the past two decades, antibody therapeutics have emerged as a crucial component in the ...
Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, Region - Global Forecast to 2028
The global antibody drug conjugates market size is projected to reach USD 19.8 billion by 2028 from USD 9.7 billion in 2023, at a CAGR of 15.2% during the forecast period. Factors such as the rising prevalence of cancer, robust products under clinical ...
Global Antibody Drug Conjugates Market - 2025-2035: Focus on Product, Application, Target, Payload Type, Linker Type, Linker Technology, and Geography
... Others Segmentation 4: by Payload Type Monomethyl Auristatin E Calicheamicin Maytansinoids Other Payload Types ...
Antibody-Drug Conjugates 2014 - a Business, Technology & Pipeline Analysis
Antibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis The report entitledAntibody-Drug Conjugates 2014 – A Business, Technology & Pipeline Analysis published in January 2014 is based on the evaluation of more than 90 companies. The ...
Enzyme-Linked Immunosorbent Assay (ELISA): Market Research Report
This report analyzes the worldwide markets for Enzyme-Linked Immunosorbent Assay (ELISA) in US$ Thousands by the following Product Segments: ELISA Development Sets and Antibody Pairs, and ELISA Kits. The report provides separate comprehensive analytics for ...
Antibody Target, Technology & Pipeline Database: 1-Year Subscription
... Antibody-Drug Conjugates per Payload (e.g. Auristatin, PBD) Bispecific Antibodies Oligo- and ...
Research ELISA (Enzyme-Linked Immunosorbent Assay): Market Research Report
This report analyzes the worldwide markets for Research ELISA (Enzyme-Linked Immunosorbent Assay) in US$ Thousand. The global market is also analyzed by the following Segments: ELISA Development Sets and Antibody Pairs, and ELISA Kits. The report provides ...
AL Amyloidosis - Pipeline Insight, 2021
... ) conjugated to the microtubule distrupter monomethyl auristatin-F (MMAF).1 Afucosylation of the Fc region of monoclonal ...
Anti-CD30 Therapies - Pipeline Insight, 2022
... linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary ...
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026
... IgG1 monoclonal antibody conjugated to monomethyl auristatin F (MMAF, mafodotin) via a non-cleavable ...
Head and Neck Squamous Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
... a potent microtubule-disrupting chemical, monomethyl auristatin E (MMAE), via a protease-cleavable linker ...
Competitor Analysis: Antibody-Drug Conjugates (ADC)
... one of the two major technologies (auristatin and maytansin derivatives) have paved ...
Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company
Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company The competitive intelligence report „Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company“ evaluates and describes the competitive landscape of antibody-drug ...
|
|
|
|
